Literature DB >> 25198041

Oldie but goodie: Repurposing penicillin for tuberculosis.

Amanda B Keener1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25198041     DOI： 10.1038/nm0914-976

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

1.  Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis.

Authors:  P R Donald; F A Sirgel; A Venter; D P Parkin; B W Van de Wal; A Barendse; E Smit; D Carman; J Talent; J Maritz
Journal:  Scand J Infect Dis       Date:  2001

2.  Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.

Authors:  M C Payen; S De Wit; C Martin; R Sergysels; I Muylle; Y Van Laethem; N Clumeck
Journal:  Int J Tuberc Lung Dis       Date:  2012-04       Impact factor: 2.373

3.  The history of tuberculosis.

Authors:  Thomas M Daniel
Journal:  Respir Med       Date:  2006-09-01       Impact factor: 3.415

4.  [The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis].

Authors:  T Iwanaga; K Yokota; R Kishikawa; T Ikeda; H Tsurutani; T Hirose; S Nishima
Journal:  Kekkaku       Date:  1997-01

5.  Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

Authors:  Saverio De Lorenzo; Jan Wilem Alffenaar; Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Simon Tiberi; Mathieu S Bolhuis; Richard van Altena; Piero Viggiani; Andrea Piana; Antonio Spanevello; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-09-20       Impact factor: 16.671

6.  European-African clinical research scheme expands into phase 1.

Authors:  Nicholette Zeliadt
Journal:  Nat Med       Date:  2014-07       Impact factor: 53.440

7.  In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

8.  Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.

Authors:  J P Nadler; J Berger; J A Nord; R Cofsky; M Saxena
Journal:  Chest       Date:  1991-04       Impact factor: 9.410

9.  Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.

Authors:  Jean-Emmanuel Hugonnet; Lee W Tremblay; Helena I Boshoff; Clifton E Barry; John S Blanchard
Journal:  Science       Date:  2009-02-27       Impact factor: 47.728

10.  Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis.

Authors:  Saugata Hazra; Hua Xu; John S Blanchard
Journal:  Biochemistry       Date:  2014-05-29       Impact factor: 3.162
View more
  13 in total

1.  Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Authors:  Shiqi Xiao; Haidan Guo; Warren S Weiner; Clinton Maddox; Chunhong Mao; Hendra Gunosewoyo; Shaaretha Pelly; E Lucile White; Lynn Rasmussen; Frank J Schoenen; Jeffrey Aubé; William R Bishai; Shichun Lun
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.

Authors:  Pankaj Kumar; Amit Kaushik; Drew T Bell; Varsha Chauhan; Fangfang Xia; Rick L Stevens; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 3.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

Authors:  Daniel T Hoagland; Jiuyu Liu; Robin B Lee; Richard E Lee
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

4.  Mechanism of MenE inhibition by acyl-adenylate analogues and discovery of novel antibacterial agents.

Authors:  Joe S Matarlo; Christopher E Evans; Indrajeet Sharma; Lubens J Lavaud; Stephen C Ngo; Roger Shek; Kanagalaghatta R Rajashankar; Jarrod B French; Derek S Tan; Peter J Tonge
Journal:  Biochemistry       Date:  2015-10-15       Impact factor: 3.162

5.  Investigating β-Lactam Drug Targets in Mycobacterium tuberculosis Using Chemical Probes.

Authors:  Samantha R Levine; Kimberly E Beatty
Journal:  ACS Infect Dis       Date:  2021-01-20       Impact factor: 5.084

Review 6.  Have we realized the full potential of β-lactams for treating drug-resistant TB?

Authors:  Elizabeth Story-Roller; Gyanu Lamichhane
Journal:  IUBMB Life       Date:  2018-06-22       Impact factor: 3.885

7.  Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection.

Authors:  Joaquín Rullas; Neeraj Dhar; John D McKinney; Adolfo García-Pérez; Joël Lelievre; Andreas H Diacon; Jean-Emmanuel Hugonnet; Michel Arthur; Iñigo Angulo-Barturen; David Barros-Aguirre; Lluís Ballell
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

8.  Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.

Authors:  Keira A Cohen; Tal El-Hay; Kelly L Wyres; Omer Weissbrod; Vanisha Munsamy; Chen Yanover; Ranit Aharonov; Oded Shaham; Thomas C Conway; Yaara Goldschmidt; William R Bishai; Alexander S Pym
Journal:  EBioMedicine       Date:  2016-06-01       Impact factor: 8.143

9.  Whole genome SNP analysis suggests unique virulence factor differences of the Beijing and Manila families of Mycobacterium tuberculosis found in Hawaii.

Authors:  Kent Koster; Angela Largen; Jeffrey T Foster; Kevin P Drees; Lishi Qian; Edward P Desmond; Xuehua Wan; Shaobin Hou; James T Douglas
Journal:  PLoS One       Date:  2018-07-23       Impact factor: 3.240

10.  Collateral Sensitivity to β-Lactam Drugs in Drug-Resistant Tuberculosis Is Driven by the Transcriptional Wiring of BlaI Operon Genes.

Authors:  A S Trigos; B W Goudey; J Bedő; T C Conway; N G Faux; K L Wyres
Journal:  mSphere       Date:  2021-05-28       Impact factor: 4.389
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.